JW Pharmaceutical Corporation (KRX:001060)
South Korea · Delayed Price · Currency is KRW 27,800
-100 (-0.36%)
At close: Sep 18, 2026
JW Pharmaceutical Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 820,862 | 775,298 | 719,376 | 748,527 | 684,351 | 606,585 |
Revenue Growth | 10.50% | 7.77% | -3.89% | 9.38% | 12.82% | 10.82% |
Gross Profit Gross Profit Growth | 388,220 | 359,314 | 323,498 | 335,542 | 287,955 | 234,376 |
Operating Income Operating Income Growth | 107,817 | 87,877 | 82,733 | 96,631 | 60,490 | 30,848 |
Net Income Net Income Growth | 97,541 | 60,648 | 65,040 | 37,006 | 31,892 | -967.85 |
Earnings Per Share EPS Growth | 4325.82 | 2676.46 | 2644.00 | 1554.67 | 1373.14 | -41.70 |
EPS Growth | 100.99% | 1.23% | 70.07% | 13.22% | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 102,084 | 61,341 | 32,551 | 94,196 | 149,678 | 65,666 |
Total Debt Total Debt Growth | 71,750 | 54,635 | 91,726 | 170,280 | 209,542 | 245,145 |
Net Cash (Debt) Net Cash Growth | 30,334 | 6,706 | -59,175 | -76,084 | -59,864 | -179,479 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 1345.26 | 295.95 | -2405.58 | -3196.37 | -2577.51 | -7733.47 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 134,478 | 96,396 | 79,392 | 87,157 | 56,764 | 18,124 |
Capital Expenditures CapEx Growth | -11,672 | -11,772 | -8,313 | -27,286 | -9,919 | -7,467 |
Free Cash Flow Free Cash Flow Growth | 122,806 | 84,625 | 71,079 | 59,871 | 46,845 | 10,657 |
Free Cash Flow Growth | 191.35% | 19.06% | 18.72% | 27.81% | 339.56% | -78.97% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 47.29% | 46.34% | 44.97% | 44.83% | 42.08% | 38.64% |
Operating Margin | 13.13% | 11.34% | 11.50% | 12.91% | 8.84% | 5.08% |
Pretax Margin | 14.05% | 11.46% | 11.46% | 7.33% | 6.63% | 3.38% |
Profit Margin | 11.88% | 7.82% | 9.04% | 4.94% | 4.66% | -0.16% |
FCF Margin | 14.96% | 10.91% | 9.88% | 8.00% | 6.84% | 1.76% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 450.000 | - | - | - | - | - |
Dividend Per Share Growth | 0% | - | - | - | - | - |
Dividend Yield | 1.62% | - | - | - | - | - |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 6.43 | 9.65 | 8.64 | 22.39 | 13.16 | - |
Forward PE | - | 6.18 | 6.50 | 14.34 | 10.40 | 26.79 |
P/FCF Ratio | 5.17 | 6.91 | 7.90 | 13.84 | 8.96 | 47.45 |
PS Ratio | 0.77 | 0.75 | 0.78 | 1.11 | 0.61 | 0.83 |